---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-194948"
form_type: "8-K"
ticker: "GRTX"
cik: "0001563577"
company_name: "Galera Therapeutics, Inc."
filed_at: "2025-09-03T23:59:59+00:00"
generated_at: "2026-05-17T08:30:45.580491+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Galera Therapeutics reduces Blackstone royalty to 4% from high single-digit on halted products

## Summary
- Amendment cuts royalty payable to Blackstone on worldwide net sales of avasopasem/rucosopasem from high single-digit % to 4%.
- Reduced rate also applies to Product Payment damages received during the royalty period.
- Company has suspended clinical development and commercial readiness for both products.
- Purchaser is Blackstone Life Sciences, successor in interest to Clarus Ventures.

## SEC filing metadata
- accession: 0001193125-25-194948
- form_type: 8-K
- ticker: GRTX
- cik: 0001563577
- company_name: Galera Therapeutics, Inc.
- filed_at: 2025-09-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563577/000119312525194948/0001193125-25-194948-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563577/000119312525194948/d478971d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-194948
- JSON: https://secwatch.observer/filing/0001193125-25-194948.json
- Plain text: https://secwatch.observer/filing/0001193125-25-194948.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.